Cancer TreatmentDownload our investor deck
Cold tumors are 5x more prevalent
than hot tumors
Our novel PD‑L2 target binds
with 5x the affinity
Preclinical data show that our lead platform may have 5x the efficacy of current treatments
The potential market is
greater than $50 billion
Creativity and focus power rational design
Our founder, Dr. Michael Curran, is laser focused on cancer. In his early career, he revolutionized the treatment of melanoma by imagining and designing the first FDA-approved immunotherapy combination: CTLA-4 and PD-1 inhibitor, which cured many patients with otherwise terminal disease.
Not willing to stop there, he established the Curran Laboratory in 2012 at MD Anderson Cancer Center with a singular goal: bring the treatment success in immunologically “hot” tumors (eg, melanoma and lung) to immune-resistant “cold” tumors (eg, prostate and colorectal). Numerous resistance mechanisms in these tumor types make this a daunting challenge. And yet, systematically, Dr. Curran has identified key resistance mechanisms and crafted targeted therapeutic interventions.Learn more about ImmunoGenesis
Turn cold tumors hot
Immunosuppressive elements in the tumor microenvironment mean that many tumors evade treatment and are hidden from cancer-destroying immune cells. Tumors are considered “hot” or “cold.” Hot tumors contain many T cells (T-cell inflamed), whereas cold tumors have immunosuppressive elements that exclude T cells. This distinction is crucial because some T cells can recognize and eliminate cancerous cells.
Cold tumors make up the majority of cancers and affect 5 times as many patients as hot tumors. Because cold tumors have unique immunosuppressive characteristics, immunotherapy is only minimally effective in treating these cancers.
We are just getting warmed up
The next several years are going to be exciting. We have several programs in the pipeline and a vision for bringing them to life.Take a look
For more information email info@ImmunoGenesis.com or complete this form: